Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry M Brenner

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
The American Journal of Cardiology|November 29, 2005
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studiesAlbert A Carr, Peter R Kowey, Richard B Devereux, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|February 16, 2012
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)Hans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.
The New England Journal of Medicine|November 6, 2012
Cardiorenal end points in a trial of aliskiren for type 2 diabetesHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane, Zhongxin Zhang, Paulette A Lyle, et al.
Diabetes Care|March 30, 2004
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL StudyJuliana C N Chan, Nelson M S Wat, Wing-Yee So, et al.
Journal of Hypertension|March 14, 2007
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studiesWouter B A Eijkelkamp, Zhongxin Zhang, Barry M Brenner, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 29, 2004
The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathyWilson Y S Leung, Wing-Yee So, Peter C Y Tong, et al.
American Journal of Nephrology|December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline CharacteristicsMeg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.
The New England Journal of Medicine|April 17, 2019
Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Meg J Jardine, Bruce Neal, et al.
Circulation|July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention GroupsKenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
The American Journal of Cardiology|November 29, 2005
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studiesAlbert A Carr, Peter R Kowey, Richard B Devereux, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|February 16, 2012
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)Hans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.
The New England Journal of Medicine|November 6, 2012
Cardiorenal end points in a trial of aliskiren for type 2 diabetesHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane, Zhongxin Zhang, Paulette A Lyle, et al.
Diabetes Care|March 30, 2004
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL StudyJuliana C N Chan, Nelson M S Wat, Wing-Yee So, et al.
Journal of Hypertension|March 14, 2007
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studiesWouter B A Eijkelkamp, Zhongxin Zhang, Barry M Brenner, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 29, 2004
The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathyWilson Y S Leung, Wing-Yee So, Peter C Y Tong, et al.
American Journal of Nephrology|December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline CharacteristicsMeg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.
The New England Journal of Medicine|April 17, 2019
Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Meg J Jardine, Bruce Neal, et al.
Circulation|July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention GroupsKenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.
Pageof 7